OTC Bulletin Board

S & P Company Insight for GEOVAX LABS INC
 
 Profile

 
Business Summary: GeoVax Labs, Inc., a biotechnology company, focuses on developing vaccines to protect against or to treat diseases caused by human immunodeficiency virus (HIV).
 
Address
  1900 Lake Park Drive, Suite 380
  Smyrna , GA 30080
  Phone: 678-384-7220
  Fax: 678-384-7281
  Website: http://www.geovax.com
Transfer Agent
  American Stock Transfer & Trust Co.
Employees:  15
ShareHolders:  1200
Founded:  1987
Domicile:  Delaware
 
  
 
 Background

 
GeoVax Labs, Inc., a biotechnology company, focuses on developing vaccines to protect against or to treat diseases caused by human immunodeficiency virus (HIV). The company's ongoing research and development programs are focused on the clinical development of its DNA and MVA vaccines for the prevention and/or treatment of HIV/AIDS. It is developing two clinical pathways for its vaccine candidates, as a preventative vaccine to prevent development of AIDS in healthy individuals who are exposed to the HIV virus and as a therapeutic vaccine to prevent development of AIDS in those individuals who have already been infected with the HIV virus. GeoVax Labs' preventative vaccine candidate is in a Phase IIa clinical trial. In addition to its clinical development program for its vaccine candidates, the company is conducting preclinical research on the impact of adding adjuvants (immune system stimulants) to its vaccine components to investigate whether they can improve the effectiveness of its vaccine candidates. GeoVax Labs is based in Smyrna, Georgia.
History:  INCORPORATED in Delaware June 17, 2008; and on June 18, 2008, merged its parent, an Illinois corporation of the same name, on a share-for-share basis. Former parent was incorporated in Illinois Apr. 26, 1991, as Dauphin Technology, Inc. On June 14, 1991, it merged Dauphin Technology, Inc., a Utah corporation (Dauphin - Utah); and on Sept. 6, 1991, it merged DT of Illinois, Inc., its wholly owned subsidiary. DT of Illinois, Inc. was incorporated in Illinois June 6, 1988, as Dauphin Technology, Inc. and was acquired by Dauphin - Utah on Apr. 4, 1991. Dauphin - Utah was originally organized in Utah as Sucesso, Inc. on Sept. 8, 1987, and changed its name to Dauphin Technology, Inc. on Apr. 5, 1991. Dauphin Technology, Inc., the Illinois corporation that was later merged, changed its name to DT of Illinois, Inc. on Apr. 23, 1991. September 28, 2006, acquired GeoVax, Inc. through a merger transaction. Following the merger, Common shareholders of GeoVax, Inc. and holders of GeoVax, Inc. Redeemable Convertible Preferred stock received a total of 490,332,103 Common shares of the company. The company changed its name to GeoVax Labs, Inc. on Sept. 28, 2006. GeoVax, Inc., the acquired concern, was incorporated in Georgia June 27, 2001.
 
Subsidiaries:
GeoVax, Inc.
 
 
Capital Expenditures, thousand. US Dollars
  Year  Amount
  2009  270
  2008  100
 
Research and Development Expenditures, thousand. US Dollars
  Year  Amount
  2009  4,068
  2008  3,741
 
  
 
 Management

 

Management
OfficersPosition
 Donald G. HildebrandChairman
 Robert T. McNallyPresident & Chief Executive Officer
 Mark W. ReynoldsSecretary, Chief Financial Officer & Chief Accounting Officer
 Harriet  RobinsonChief Scientific Officer
 James  CarbonaraInvestor Relations Contact

Directors
 Steven S. Antebi
 David A. Dodd
 Donald G. Hildebrand
 Dean G. Kollintzas
 Robert T. McNally
 Harriet  Robinson
 John N. Spencer, Jr.
 Peter M. Tsolinas
 
  
 
 Annual Report

 
Annual Report
 
Income Statement
  200920082007
REVENUES
Grant Revenues3,668,1952,910,170237,004
EXPENSES
General and Administrative(2,914,845)(2,970,068)(2,784,182)
Research and Development(4,068,682)(3,741,489)(1,757,125)
Interest Income31,08073,20062,507
Earnings before Taxes(3,284,252)(3,728,187)(4,241,796)
TAXES AND OTHER EXPENSES
Net Income (Loss)(3,284,252)(3,728,187)(4,241,796)
SUPPLEMENTARY INFO
Operating Income (Loss)(3,315,332.00)(3,801,387.00)(4,304,303.00)
Basic EPS - Continuing OperationsNil(0.01)(0.01)
Diluted EPS - Continuing OperationsNil(0.01)(0.01)
 
Balance Sheet
  20092008
CURRENT ASSETS
Cash and Cash Equivalents3,515,7842,191,180
Grant Funds Receivable320,321311,368
Prepaid Expenses and Other44,615299,286
Total Current Assets3,880,7202,801,834
NON CURRENT ASSETS
Property and Equipment344,202138,847
Licenses89,695114,580
Deposits and Other980980
Total Assets4,315,5973,056,241
CURRENT LIABILITIES
Accounts Payable and Accrued Expenses408,344176,260
Amounts Payable to Emory University163,021170,162
Total Current Liabilities571,365346,422
SHAREHOLDERS' EQUITY
Common Stock - Par Value781,628747,449
Additional Paid in Capital20,500,45016,215,970
Deficit Accumulated during the Development Stage(17,537,850)(14,253,600)
Total Shareholders Equity3,744,2322,709,819
Total Liabilities & Shareholders Equity4,315,5973,056,241
 
  
 
 Interim Report

 
Interim Report   
 
Data Not Available
 
 
 
 
  
 
 Pro Forma Report

 
Pro Forma Report   
 
Data Not Available
 
 
 
 
  
 
 Quarterly Report

 
Quarterly Report Information   
 
Quarterly Revenue, US$
YearQuarterRevenue
  2010   11,340,000
  2009   1710,000
  2009   2750,000
  2009   31,810,000
  2009   4400,000
  2009   Full Year 3,670,000
  2008   1600,000
  2008   2380,000
  2008   31,320,000
  2008   4610,000
  2008   Full Year 2,910,000
  2007   1Nil
  2007   2Nil
  2007   3Nil
  2007   4240,000
  2007   Full Year 240,000
  2006   1Nil
  2006   2480,000
  2006   3Nil
  2006   4370,000
  2006   Full Year 850,000
  2005   1170,000
  2005   260,000
  2005   3430,000
  2005   420,000
  2005   Full Year 670,000
 
 
Quarterly Net Income, US$
YearQuarterRevenue
  2010   1(690,000)
  2009   1(860,000)
  2009   2(1,350,000)
  2009   3(230,000)
  2009   4(840,000)
  2009   Full Year (3,280,000)
  2008   1(680,000)
  2008   2(1,280,000)
  2008   3(720,000)
  2008   4(1,040,000)
  2008   Full Year (3,730,000)
  2007   Full Year (4,240,000)
  2006   Full Year (580,000)
  2005   Full Year (1,610,000)
 
 
Quarterly EPS, US$
YearQuarterRevenue
  2010   1(.04)
  2009   1(.06)
  2009   2Nil
  2009   3Nil
  2009   4Nil
  2009   Full Year Nil
  2008   1Nil
  2008   2Nil
  2008   3Nil
  2008   4Nil
  2008   Full Year (.50)
  2007   1Nil
  2007   2Nil
  2007   3Nil
  2007   4(.50)
  2007   Full Year (.50)
  2006   1Nil
  2006   2Nil
  2006   3Nil
  2006   4Nil
  2006   Full Year Nil
  2005   1Nil
  2005   2Nil
  2005   3Nil
  2005   4(.50)
  2005   Full Year (.50)
 
  
 
 Stock Data

 
 
Capitalization as of 03/31/2010:
 
 Authorized SharesOutstanding Shares
Common $0.001 par40,000,00015,652,814so1
Preferred $0.001 par10,000,000None
 
LONG TERM DEBT: None.
 
Common $0.001 par
 
Stockholders:  05/20/2010, 1200.
PRINCIPAL STOCKHOLDERS: May 21, 2010, Emory University owned or controlled 29.5% of the Common, and Welch & Forbes LLC 10.1%.
 
Transfer Agent:  American Stock Transfer & Trust Co.   New York , NY
 
OTC Bulletin Board( Primary): GOVX
 
ExchangeYearHighLow
OTC Bulletin Board20090.38000.0900
OTC Bulletin Board20080.29000.0900
OTC Bulletin Board20070.50000.1610
OTC Bulletin Board20061.16000.1850
 
DIVIDENDS: Common $0.001 par: No cash. Common reverse split 1-for-50, Apr. 28, 2010.
 
 
  so1Adjtd. for 1-for-50 reverse split Apr. 28, 2010.